Rathin C. Das, Ph.D., MBA
Chief Executive Officer
Dr. Das has more than 30 years of experience in big pharma and biotech industry focusing on the biotherapeutics sector in general, and the therapeutic antibody area, in particular. Immediately prior to founding Synergys, he worked for 9 years for Affitech AS of Oslo, Norway, an antibody therapeutics company, of which he was the Senior Vice President of Corporate Development and Chief Business Officer and the President of its US operations, Affitech USA, Inc. As the CBO of Affitech, Dr. Das was instrumental in building the expanding commercial and licensing agreements of Affitech AS and was responsible for various aspects of the Company’s corporate development activities including the expansion and management of the US subsidiary. He also assisted at the highest management level in several external fundraising efforts of multimillion dollar total valuation for Affitech. Previously, Dr. Das has held research management positions as Section Head at Bayer Corporation in the United States and worked at Bayer AG in Germany in an executive exchange program. Besides having a PhD in Bioorganic Chemistry and an MBA (Executive Programme), Dr. Das carried out several years of post-doctoral research in cellular and molecular biology at the University of Iowa, Iowa City and at the Cancer Research Center, Massachussetts Institute of Technology, Cambridge, USA. He has published numerous articles in both peer-reviewed and trade journals and was a Contributing Editor of the American Biotechnology Laboratory, a biotech trade journal published by the International Scientific Communications.
Linda Pullan, Ph.D.
Vice President, Business Development & Marketing
Dr. Pullan is President of Pullan Consulting, offering all the elements of business development and drawing upon over 20 years of pharmaceutical and biotech experience. She provides in-depth understanding and proven success in drug development, and evaluation, valuation and negotiation for strategic alliances and licensing deals. Prior to founding Pullan Consulting, she was the Vice President of Business Devleopment at Kosan Biosciences, Inc. and held management positions at business development departments of Amgen, Inc. and Zeneca Pharmaceuticals. Dr. Pullan started her research career at what is now Pfizer, and as a project team leader at Zeneca (currently AstraZeneca) contributing to the development of Seroquel, the multi-billion dollar anti-psychotic drug. Following to that she switched to licensing, and subsequently joined Amgen and was the Director and head of oncology and hematology licensing of the Company, which position she relinquished to become VP of business development at Kosan Biosciences in 2004. Dr. Pullan has a PhD in biochemistry from the University of California, riverside. She authored 66 scientific literature publications; and is the Editor of a book Neurotherapeutics: Emerging Strategies.
Lucia Beviglia, Ph.D.
Director of R&D Projects
Dr. Beviglia is the President of Beviglia Cancer Models, LLC a consulting and service provider Company that helps investigators develop new cancer treatments through preclinical development. She has more than 25 years of experience working in the fields of cancer biology, pharmacology, hematology, angiogenesis, and immunology at academia and industry. Dr. Beviglia is highly experienced in developing orthotopic and subcutaneous human tumor models, including the patient-derived xenografts (PDXs) of several types of cancer (breast, ovarian, pancreatic, melanoma, and leukemia/lymphoma) and syngeneic models, and angiogenesis assays. With her strong expertise in preclinical pharmacological modeling, design and execution of efficacy cancer studies she has routinely serviced clients in evaluating primary tumor growth and metastatic dissemination in response to new cancer treatments including immunotherapies (chimeric antigen receptor T cells, virus-like particles, immuno-modulators), and cytotoxic treatments. She helped Corgentech to establish their first cancer program that contributed to the product pipeline advanced into IND and IPO filings. She also supported the clinical development of anti-cancer stem cells antibodies at OncoMed Pharmaceuticals. Dr. Beviglia obtained her Ph.D in Biological Sciences from the University of Perugia, Perugia, Italy and carried out several years of postdoctoral research at Temple University, Philadelphia, PA and at the University of California San Francisco, San Francisco, CA. She has authored more than 20 publications.
Bruce E. Carrier, CPA
Mr. Carrier currently leads a family office services practice, as well as advising startup companies. Previously, he managed a high-net-worth family office and their property development business activities for over 15 years. Prior to that, he spent ten years in lead accounting and finance roles with a fast-growing, publicly traded, $500 million alternative energy company with over 1,000 employees. The company provided alternative energy through the design and manufacture of advanced technology wind turbines and the development, construction, financing, operation and maintenance of co-generation, bio-mass, demand-side and wind power electrical generating/conserving facilities. Mr. Carrier obtained his CPA license while working for five years as an auditor and business consultant with a Big-8 accounting firm (Arthur Andersen & Co) , plus, two years with the DOD as a contract auditor and member of their computer audit specialty team.